Phase 2 Lung Cancer Trial, Not Yet Recruiting NCT06497543 Sponsor: Hunan Province Tumor Hospital Condition: Lung Cancer
Back to Lung Cancer

Phase 2 Lung Cancer Trial, Not Yet Recruiting

NCT06497543
Not Yet Recruiting Phase 2

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People who understand what the trial involves and are willing to sign a dated consent form.
  • People aged 18 years or older.
  • People who have been diagnosed with small cell lung cancer confirmed by tissue testing.
  • People who have cancer that has spread to the membranes surrounding the brain or spinal cord (leptomeningeal metastasis), confirmed by symptoms, spinal fluid testing, genetic analysis of spinal fluid, or imaging results.
  • People whose brain cancer has continued to grow or returned after whole-brain radiotherapy.
  • People expected to survive for at least 12 weeks.
  • People with a general health and activity level rated between 0 and 2 on a standard medical scale (meaning largely able to care for themselves, confirm with trial site).
  • People with adequately functioning bone marrow and major organs such as the liver and kidneys (confirm with trial site).

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who have previously received a chemotherapy drug called pemetrexed injected directly into the spinal fluid.
  • People who have had radiotherapy within 14 days before the first dose and have not fully recovered from its side effects (some types of targeted radiotherapy may be allowed if given at least 7 days before the first dose — confirm with trial site).
  • People who have spinal cord compression or cancer that has spread to the membranes around the brain or spinal cord.
  • People who have had another cancer within the past 2 years.
  • People still experiencing side effects (other than hair loss) from previous treatments that are rated above a mild level on a standard medical scale.
  • People who have had a stroke or bleeding in the brain within the 6 months before the first dose.
  • People with serious or poorly managed conditions such as uncontrolled high blood pressure or active bleeding.
  • People with ongoing or active infections, including hepatitis B, hepatitis C, HIV, or COVID-19.
  • People with significant heart-related conditions or abnormalities (confirm with trial site).
  • People with a history of lung scarring or inflammation of the lung tissue, including cases caused by previous drug treatments, radiotherapy, or immunotherapy.
  • People with severe nausea or vomiting that cannot be controlled, long-term digestive conditions, difficulty swallowing, or problems absorbing medication due to previous bowel surgery.
  • People who received a live vaccine within 2 weeks before the first dose.
  • People who are pregnant or currently breastfeeding.
  • People with known allergies to the study drugs or their ingredients.
  • People whom the trial doctors consider unsuitable for the study for any other reason.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 17 July 2026

Contact this trial

Phone: +8613873123436

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Phase 2
Sponsor
Hunan Province Tumor Hospital
Registry
ClinicalTrials.gov
Start date
1 October 2024
Est. completion
31 October 2025

This date has passed while the registry still lists the trial as open to participants. Sponsors often update a trial's status without revising its projected end date, so it may well still be recruiting — but the record is out of date in at least one respect. Check with the study contact before relying on either.

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Overall Survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 17 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov